Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III evaluation of the safety and efficacy of Clonicel (clonidine HCl sustained release) as add-on to psychostimulant medication vs. psychostimulant medication alone in children and adolescents with ADHD

Trial Profile

Phase III evaluation of the safety and efficacy of Clonicel (clonidine HCl sustained release) as add-on to psychostimulant medication vs. psychostimulant medication alone in children and adolescents with ADHD

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 May 2011

At a glance

  • Drugs Clonidine (Primary) ; Central nervous system stimulants
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Addrenex Pharmaceuticals
  • Most Recent Events

    • 09 May 2011 Results published in the Pediatrics.
    • 09 May 2011 Results have been published in Pediatrics according to a Shionogi media release.
    • 04 Oct 2010 The US FDA has approved clonidine extended-release tablets based on results from this and another (32491) trial, according to a Shinogi Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top